In addition to proteasome inhibition, Millennium is pursuing other therapeutic strategies for cancer, including the use of monoclonal antibodies conjugated to radioisotopes or chemotherapeutic agents, small-molecule targeting DNA/RNA inhibitors of enzymes involved in cellular replication, and small-molecule inhibitors of faulty kinase-mediated signaling in malignant cells.
In addition to
VELCADE® (bortezomib) for Injection, our pipeline of development candidates includes the following investigational drugs:
Further information about these investigational drugs is available in the
R&D section of this website.
